Cost-effectiveness of new oral anticoagulants and warfarin in atrial fibrillation from adverse events perspective
Rev. colomb. cardiol; 26 (2), 2019
Abstract Objective: new oral anticoagulants (apixaban, dabigatran and rivaroxaban) are the newest advance for stroke's risk reduction in atrial fibrillation. These are as effective as warfarin in preventing stroke/systemic embolism, but exists heterogenic outcomes as gastrointestinal hemorrhage, mortali...